Trials / Unknown
UnknownNCT05728684
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Recurrent IgG4-related Diseases
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.
Detailed description
This study includes three stages: screening period, treatment period and safety follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | CM310 Injection |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
- First posted
- 2023-02-15
- Last updated
- 2023-02-15
Source: ClinicalTrials.gov record NCT05728684. Inclusion in this directory is not an endorsement.